SCHEDULE: Armistice Capital Reports 4.99% Stake in Adial Pharmaceuticals

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 274,139 shares, representing 4.99% of Adial Pharmaceuticals, Inc.'s common stock.

Summary

• Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, indicating their beneficial ownership of 274,139 shares of Adial Pharmaceuticals, Inc. common stock.
• This holding represents 4.99% of the total class of securities.
• Armistice Capital, LLC acts as the investment manager for the Master Fund, which directly holds the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, may be deemed to beneficially own these shares.
• The filing is made under Rule 13d-1(b) and is not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports a significant ownership stake but provides no operational or financial performance data for Adial Pharmaceuticals, Inc., making it difficult to infer positive or negative sentiment about the company itself.

Positives

• Armistice Capital, LLC and Steven Boyd have disclosed a significant, though below the 5% threshold for active reporting, ownership stake in Adial Pharmaceuticals, Inc.
• The filing indicates that the shares were acquired and are held in the ordinary course of business, suggesting a passive investment strategy rather than an attempt at control.

Negatives

• The filing does not contain any specific financial performance data or operational updates for Adial Pharmaceuticals, Inc., making it difficult to assess the company's underlying health.
• The Master Fund, the direct holder of the shares, disclaims beneficial ownership due to its investment management agreement with Armistice Capital, which could imply a complex ownership structure.

Risks

• The filing does not explicitly detail any risks associated with Adial Pharmaceuticals, Inc. or the investment itself.
• Potential future changes in beneficial ownership by Armistice Capital or other investors could impact the stock price.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Adial Pharmaceuticals, Inc.'s future performance. It solely reports on beneficial ownership.

Management Comments

• Armistice Capital, LLC exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating stakes in publicly traded companies. This filing by Armistice Capital indicates a significant, but not controlling, interest in Adial Pharmaceuticals, Inc., a biotechnology company, suggesting a potential for increased institutional attention or a passive investment strategy.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an institutional investor like Armistice Capital may be viewed positively by some shareholders, potentially indicating confidence in the company's long-term prospects, though the passive nature of the filing limits immediate impact.
• Management of Adial Pharmaceuticals, Inc.: The company's management will be aware of Armistice Capital's holdings and their stated intention to not influence control, which could shape future strategic communications.
• Potential Investors: This filing provides transparency to other investors regarding significant ownership, which can be a factor in their investment decisions.

Next Steps

• Armistice Capital, LLC and Steven Boyd will continue to hold their shares in Adial Pharmaceuticals, Inc.
• Future amendments to this Schedule 13G will be filed if there are any changes in beneficial ownership.

Key Dates

Keywords

Adial Pharmaceuticals, Schedule 13G, Armistice Capital, Steven Boyd, beneficial ownership, common stock, SEC filing, investment management